Shaun Hawkins
Managing Partner, Pier 70 Ventures
Shaun Hawkins is managing partner at Pier 70 Ventures, a fund focused on investing in impact-driven healthcare innovation. In 2015, Shaun founded the ProSyte Companies, a diversified holding entity investing in healthcare businesses and real estate in the US and Europe.
Shaun joined Eli Lilly and Company in 2001 and initially held various roles in licensing and corporate business development. In 2009, he was promoted to chief diversity officer. From 2012 until his departure in 2015, Shaun was vice president of new ventures and private equity investing at Lilly. He was responsible for the company’s venture capital, private equity and venture formation activities, managing over $1.4 billion.
Shaun currently serves on the board of directors for Invesque, Inc. (TSX: IVQ.U), where he chairs the governance and nominating committee and is a member of the audit committee. He was the previous board chair for Audion Therapeutics (Netherlands) and Muroplex Therapeutics (US) as well as a board member of the Accelerator Corporation (US), Immuneworks Inc. (US) and Zymeworks Inc. (Canada). He was also a member of the limited partner advisory committees of BioCrossroads’ Indiana Enterprise Fund (US), Epidarex Capital (UK), the Indiana Future Fund/INext Fund (US) and TVM Capital (Canada and Germany). In 2017, Hawkins earned a Board Governance Fellowship from the National Association of Corporate Directors (US).
Hawkins graduated magna cum laude with a bachelor’s degree in business from the University of Tennessee. He received his master’s degree in business administration from the Kellogg School of Management at Northwestern University.
Shaun joined Eli Lilly and Company in 2001 and initially held various roles in licensing and corporate business development. In 2009, he was promoted to chief diversity officer. From 2012 until his departure in 2015, Shaun was vice president of new ventures and private equity investing at Lilly. He was responsible for the company’s venture capital, private equity and venture formation activities, managing over $1.4 billion.
Shaun currently serves on the board of directors for Invesque, Inc. (TSX: IVQ.U), where he chairs the governance and nominating committee and is a member of the audit committee. He was the previous board chair for Audion Therapeutics (Netherlands) and Muroplex Therapeutics (US) as well as a board member of the Accelerator Corporation (US), Immuneworks Inc. (US) and Zymeworks Inc. (Canada). He was also a member of the limited partner advisory committees of BioCrossroads’ Indiana Enterprise Fund (US), Epidarex Capital (UK), the Indiana Future Fund/INext Fund (US) and TVM Capital (Canada and Germany). In 2017, Hawkins earned a Board Governance Fellowship from the National Association of Corporate Directors (US).
Hawkins graduated magna cum laude with a bachelor’s degree in business from the University of Tennessee. He received his master’s degree in business administration from the Kellogg School of Management at Northwestern University.